Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.64 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.51 |
| ▸ | LCK | P06239 | 2/20 | 0.51 |
| ▸ | KIT | P10721 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1892898 | 0.94 | MAPK14 (0.64) | MAPK14MAPKAPK2LCKKITKDR | |
| SCHEMBL1885642 | 0.88 | MAPK14 (0.82) | MAPK14MAPKAPK2LCKKITKDR | |
| SCHEMBL1892600 | 0.82 | MAPK14 (0.55) | MAPK14MAPKAPK2LCKKITKDR | |
| SCHEMBL1882591 | 0.81 | MAPK14 (0.48) | MAPK14MAPKAPK2LCKKITKDR | |
| SCHEMBL1889876 | 0.74 | MAPK14 (0.60) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3632376 | 0.74 | MAPK14 (1.00) | MAPK14MAPKAPK2LCKKITKDR | |
| SCHEMBL3640835 | 0.70 | MAPK14 (0.82) | MAPK14MAPKAPK2LCKKITKDR | |
| SCHEMBL1882817 | 0.70 | MAPK14 (0.57) | MAPK14MAPKAPK2LCKKITKDR | |
| SCHEMBL3635641 | 0.69 | MAPK14 (0.39) | MAPK14MAPKAPK2LCKKITKDR | |
| SCHEMBL3636242 | 0.69 | MAPK14 (0.85) | MAPK14MAPKAPK2LCKKITKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022085-B2 | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof | AMGEN INC. (US) | 2011-09-20 | — | — | US | claimed |
| US-20110105498-A1 | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof | AMGEN INC. (US) | 2011-05-05 | — | — | US | claimed |
| US-8435987-B2 | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof | AMGEN INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110294805-A1 | PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-8022085-B2 | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof | AMGEN INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110105498-A1 | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof | AMGEN INC. (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294805-A1 | PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF | MAPK1, MAP4K2, MAP3K1 | MAPK14 32/4885MAPKAPK2 11/4885LCK 309/4885 |
| US-20110105498-A1 | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof | MAPK1, MAP4K2, MAP3K1 | MAPK14 32/4885MAPKAPK2 11/4885LCK 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.